JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. nork Chen, E, Ahn, J, Massie, C, Clynes, D, Godfrey, A, Li, J, Park, H, Nangalia, J, Silber, Y, Mullally, A, Gibbons, R, Green, A

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline nork McMullin, M, Harrison, C, Ali, S, Cargo, C, Chen, F, Ewing, J, Garg, M, Godfrey, A, Knapper, S, McLornan, D, Nangalia, J, Sekhar, M, Wadelin, F, Mead, A

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis nork McMullin, M, Mead, A, Ali, S, Cargo, C, Chen, F, Ewing, J, Garg, M, Godfrey, A, Knapper, S, McLornan, D, Nangalia, J, Sekhar, M, Wadelin, F, Harrison, C

Hydroxycarbamide plus Aspirin vs Aspirin alone in patients with essential Thrombocythaemia aged 40-59 years without high-risk features nork Buck, G, Godfrey, A, Campbell, P, MacLean, C, Cook, J, Temple, J, Wilkins, B, Wheatley, K, Nangalia, J, Grinfeld, J, McMullin, M, Forsyth, C, Kiladjian, J, Green, A, Harrison, C

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial nork Mesa, R, Vannucchi, A, Mead, A, Egyed, M, Szoke, A, Suvorov, A, Jakucs, J, Perkins, A, Prasad, R, Mayer, J, Demeter, J, Ganly, P, Singer, J, Zhou, H, Dean, J, te Boekhorst, P, Nangalia, J, Kiladjian, J, Harrison, C

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline nork McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF

Classification and personalized prognosis in myeloproliferative neoplasms nork Grinfeld, J, Nangalia, J, Baxter, E, Wedge, D, Angelopoulos, N, Cantrill, R, Godfrey, A, Papaemmanuil, E, Gundem, G, Maclean, C, Cook, J, O'Neil, L, O'Meara, S, Teague, J, Butler, A, Massie, C, Williams, N, Nice, F, Andersen, C, Hasselbalch, H, Guglielmelli, P, McMullin, M, Vannucchi, A, Harrison, C, Gerstung, M, Green, A, Campbell, P

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial nork Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer nork Ju, Y, Alexandrov, L, Gerstung, M, Martincorena, I, Nik-Zainal, S, Ramakrishna, M, Davies, H, Papaemmanuil, E, Gundem, G, Shlien, A, Bolli, N, Behjati, S, Tarpey, P, Nangalia, J, Massie, C, Butler, A, Teague, J, Vassiliou, G, Green, A, Du, M, Unnikrishnan, A, Pimanda, J, Teh, B, Munshi, N, Greaves, M, Vyas, P, El-Naggar, A, Santarius, T, Collins, V, Grundy, R, Taylor, J, Hayes, D, Malkin, D, Foster, C, Warren, A, Whitaker, H, Brewer, D, Eeles, R, Cooper, C, Neal, D, Visakorpi, T, Isaacs, W, Bova, G, Flanagan, A, Futreal, P, Lynch, A, Chinnery, P, McDermott, U, Stratton, MR, Campbell, P